Clinical Trials
78 trialsBlinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma
National Cancer Institute (NCI)
Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)
Acerta Pharma BV
A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia
National Cancer Institute (NCI)
EPCORE DLBCL-1
Genmab
MAJIC
AstraZeneca
MANGROVE
BeOne Medicines
BRUIN-MCL-321
Eli Lilly and Company
Assessing the Ability of Combination Treatment With Venetoclax to Permit Time Limited Therapy in Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
AbbVie
Studying the Effect of Levocarnitine in Protecting the Liver From Chemotherapy for Leukemia or Lymphoma
Children's Oncology Group
A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Acerta Pharma BV
Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)
BeOne Medicines
OLYMPIA-4
Regeneron Pharmaceuticals
GLOW
Janssen Research & Development, LLC
SUNMO
Hoffmann-La Roche
Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission
Eastern Cooperative Oncology Group
Celestimo
Hoffmann-La Roche
firmMIND
Incyte Corporation
A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL) in China
Genmab
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed High-Risk B Acute Lymphoblastic Leukemia and Ph-Like TKI Sensitive Mutations
National Cancer Institute (NCI)
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia
Children's Oncology Group
Immunotherapy (Nivolumab or Brentuximab Vedotin) Plus Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage III-IV Classic Hodgkin Lymphoma
National Cancer Institute (NCI)
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
National Cancer Institute (NCI)
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to the Usual Treatment (Ibrutinib and Obinutuzumab) in Untreated, Older Patients With Chronic Lymphocytic Leukemia
National Cancer Institute (NCI)
CLL17
German CLL Study Group
LOTIS 5
ADC Therapeutics S.A.
BRUIN CLL-321
Eli Lilly and Company
PD1-VEN-CAG
Fujian Medical University Union Hospital
SYMPHONY-1
Ipsen
ECHELON-3
Seagen Inc.
LEDA
Novartis
EPCORE DLBCL-4
Genmab
A Phase III Study Evaluating Glofitamab in Combination With Gemcitabine + Oxaliplatin vs Rituximab in Combination With Gemcitabine + Oxaliplatin in Participants With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
frontMIND
Incyte Corporation
ESCALADE
Acerta Pharma BV
CCCG-ALCL-2020 for Chinese Children and Adolescents With Newly Diagnosed High-risk ALCL
Children's Cancer Group, China
LBL-2016 for Children or Adolescents in China
Children's Cancer Group, China
A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)
Merck Sharp & Dohme LLC
SEQUOIA
BeOne Medicines
Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic Leukemia
AstraZeneca
Orca-T
Orca Biosystems, Inc.
Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune Regulators' Expression
Dartmouth-Hitchcock Medical Center
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
Acerta Pharma BV
GOLSEEK-1
Celgene
OLYMPIA-2
Regeneron Pharmaceuticals
BRUIN CLL-322
Eli Lilly and Company
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents
Dana-Farber Cancer Institute